Immunovant, Inc. (IMVT)
Largest Insider Buys in Sector
IMVT Stock Price History Chart
IMVT Stock Performance
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is …
Insider Activity of Immunovant, Inc.
Over the last 12 months, insiders at Immunovant, Inc. have bought $0 and sold $11.14M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $35.04M and sold $7.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,526,316 shares for transaction amount of $58M was made by Roivant Sciences Ltd. () on 2023‑10‑02.
List of Insider Buy and Sell Transactions, Immunovant, Inc.
| 2024-10-23 | Sale | Chief Legal Officer | 4,361 0.003% | $29.53 | $128,780 | 0.00% | ||
| 2024-10-23 | Sale | Chief Technology Officer | 2,740 0.0019% | $29.53 | $80,912 | 0.00% | ||
| 2024-10-23 | Sale | Chief Medical Officer | 3,189 0.0022% | $29.53 | $94,171 | 0.00% | ||
| 2024-10-16 | Sale | Chief Executive Officer | 9,095 0.0063% | $28.79 | $261,845 | +0.81% | ||
| 2024-10-16 | Sale | Chief Medical Officer | 3,188 0.0022% | $28.79 | $91,783 | +0.81% | ||
| 2024-10-16 | Sale | Chief Financial Officer | 3,271 0.0023% | $28.79 | $94,172 | +0.81% | ||
| 2024-10-16 | Sale | Chief Legal Officer | 2,860 0.002% | $28.79 | $82,339 | +0.81% | ||
| 2024-10-09 | Sale | Chief Executive Officer | 4,460 0.0032% | $29.56 | $131,838 | -2.00% | ||
| 2024-10-09 | Sale | Chief Financial Officer | 5,162 0.0037% | $29.56 | $152,589 | -2.00% | ||
| 2024-08-21 | Sale | Chief Executive Officer | 15,068 0.0101% | $31.86 | $480,052 | -8.84% | ||
| 2024-08-21 | Sale | Chief Development Officer | 3,027 0.002% | $31.86 | $96,437 | -8.84% | ||
| 2024-08-21 | Sale | Chief Medical Officer | 3,027 0.002% | $31.86 | $96,437 | -8.84% | ||
| 2024-08-21 | Sale | Chief Financial Officer | 3,768 0.0025% | $31.86 | $120,045 | -8.84% | ||
| 2024-08-21 | Sale | Chief Legal Officer | 3,295 0.0022% | $31.86 | $104,976 | -8.84% | ||
| 2024-07-24 | Sale | Chief Legal Officer | 4,015 0.0027% | $27.76 | $111,456 | 0.00% | ||
| 2024-07-24 | Sale | Chief Technology Officer | 2,813 0.0019% | $27.76 | $78,089 | 0.00% | ||
| 2024-07-24 | Sale | Chief Medical Officer | 3,456 0.0023% | $27.76 | $95,939 | 0.00% | ||
| 2024-07-17 | Sale | Chief Executive Officer | 8,685 0.0059% | $29.69 | $257,888 | -1.85% | ||
| 2024-07-17 | Sale | Chief Development Officer | 2,867 0.0019% | $29.69 | $85,132 | -1.85% | ||
| 2024-07-17 | Sale | Chief Medical Officer | 3,044 0.0021% | $29.69 | $90,386 | -1.85% |
Insider Historical Profitability
| Butchko Julia G. | Chief Development Officer | 440959 0.3013% | $31.39 | 1 | 22 | <0.0001% |
| MIGAUSKY GEORGE V | director | 109808 0.075% | $31.39 | 1 | 1 | <0.0001% |
| Fromkin Andrew J. | director | 88658 0.0606% | $31.39 | 1 | 1 | <0.0001% |
| Pande Atul | director | 83158 0.0568% | $31.39 | 2 | 1 | +99.07% |
| Roivant Sciences Ltd. | 79805331 54.5241% | $31.39 | 5 | 0 | +39.82% |
Institutional Investor Ownership
| Fidelity Investments | $247.36M | 5.24 | 7.66M | -2.79% | -$7.1M | 0.02 | |
| The Vanguard Group | $209.31M | 4.44 | 6.48M | +11.16% | +$21.02M | <0.01 | |
| BlackRock | $144.65M | 3.07 | 4.48M | -1.19% | -$1.74M | <0.01 | |
| State Street | $117.67M | 2.49 | 3.64M | +13.23% | +$13.75M | 0.01 | |
| Perceptive Advisors | $95.74M | 2.03 | 2.96M | +27.28% | +$20.52M | 0.06 |